Summary and next episodes
Downloadable resources
In this video, Prof. Yves Dauvilliers explores narcolepsy type 1 through a practical, case-based lens, focusing on the key role of orexin deficiency in driving symptoms. He highlights the unmet needs in current treatment approaches, including ongoing residual symptoms and reliance on polypharmacy, and looks ahead to emerging orexin-targeted therapies that may redefine disease management and improve outcomes for patients.
Clinical takeaways
- Narcolepsy type 1 is characterised by selective loss of hypothalamic orexin/hypocretin neurons, resulting in reduced excitatory drive to monoaminergic and cortical wake-promoting networks. This destabilises the sleep–wake boundary, leading to excessive daytime sleepiness and dysregulated REM sleep, including cataplexy
- Patients continue to experience residual disease burden despite guideline-recommended therapy, highlighting the need for novel therapeutic approaches. Selective hypocretin receptor agonists are a promising new class designed to directly restore orexin signalling
- Oveporexton phase 3 trials (FirstLight and RadiantLight) demonstrated significant improvement in mean sleep latency on the Maintenance of Wakefulness Test (MWT) by week 12, with no treatment-related serious treatment-emergent adverse events (TEAEs). The most common adverse events were insomnia and urinary frequency or urgency, generally mild to moderate, early-onset and transient
- Alixorexton phase 2 data (Vibrance-1) showed achievement of normative wakefulness across doses (4, 6 and 8 mg), with no serious TEAEs. Adverse events were mostly early-onset, mild to moderate and included pollakiuria, insomnia and salivary hypersecretion
Download slides - PDF 
Duration
Language(s)
5 MIN
Mar 2026 
Downloadable 
